Jupiter Topco LLC acquired a new stake in Prestige Consumer Healthcare Inc. (NYSE:PBH – Free Report) during the second quarter, according to its most recent filing with the SEC. The firm acquired 22,589 shares of the company’s stock, valued at approximately $1,068,000.
Other hedge funds also recently modified their holdings of the company. BlackRock Inc. acquired a new position in shares of Prestige Consumer Healthcare during the 2nd quarter worth about $370,187,000. Rice Hall James & Associates LLC acquired a new stake in shares of Prestige Consumer Healthcare in the 2nd quarter valued at approximately $32,602,000. The Manufacturers Life Insurance Company bought a new position in Prestige Consumer Healthcare during the 2nd quarter worth approximately $31,135,000. Norges Bank bought a new position in Prestige Consumer Healthcare during the 4th quarter worth approximately $36,954,000. Finally, Bank of New York Mellon Corp acquired a new position in Prestige Consumer Healthcare during the second quarter valued at approximately $15,376,000. Institutional investors own 99.95% of the company’s stock.
Prestige Consumer Healthcare Stock Down 0.7%
Prestige Consumer Healthcare stock opened at $52.17 on Friday. The company has a debt-to-equity ratio of 1.06, a current ratio of 3.23 and a quick ratio of 1.99. The company’s 50-day moving average is $50.76 and its 200-day moving average is $54.14. The firm has a market capitalization of $2.47 billion, a PE ratio of 14.61, a P/E/G ratio of 1.64 and a beta of 0.33. Prestige Consumer Healthcare Inc. has a fifty-two week low of $42.62 and a fifty-two week high of $71.07.
Analysts Set New Price Targets
Several equities research analysts have commented on PBH shares. Oppenheimer downgraded shares of Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Zacks Research raised Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research note on Monday, August 10th. Weiss Ratings downgraded shares of Prestige Consumer Healthcare from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, June 25th. Finally, Canaccord Genuity Group cut their price objective on shares of Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a research report on Friday, May 15th. Two research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $70.75.
Get Our Latest Stock Report on PBH
Prestige Consumer Healthcare Profile
Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.
Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).
Recommended Stories
- Five stocks we like better than Prestige Consumer Healthcare
- Zscaler’s Strong Quarter Still Left Investors Waiting on 1 Key Signal
- Is Duolingo the Next Netflix-Style Comeback Story?
- GitLab’s AI Tools Are Starting to Turn Developer Demand Into Real Revenue
- GTA VI’s Console Problem Isn’t Take-Two’s Problem
Receive News & Ratings for Prestige Consumer Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prestige Consumer Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
